Raymond James reiterated a Strong Buy rating and $125 price target on Dianthus (DNTH) after the company reported data from Part A of its Phase 3 CAPTIVATE study evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy. The study showed a 75% responder rate in the first roughly 50 patients, which is notably higher than the overall rate in Sanofi's (SNY) riliprubart Phase 2 study at week 24, the analyst tells investors in a research note. The firm said the responder rate beat its expectations, and that the response was shown broadly across multiple metrics. The firm added that study design could be the "big winner" here, as it is convinced a randomized withdrawal study design with a time-to-relapse endpoint is inherently less risky than the design in MOBILIZE, where riliprubart failed.
